Neuralstem, Inc. (CUR) Reaches New 1-Year Low at $1.13

Shares of Neuralstem, Inc. (NASDAQ:CUR) reached a new 52-week low on Tuesday . The stock traded as low as $1.13 and last traded at $1.13, with a volume of 551,074 shares. The stock had previously closed at $1.26.

Separately, ValuEngine cut Neuralstem from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th.

The firm has a 50 day moving average of $4.95 and a 200-day moving average of $4.57. The stock’s market capitalization is $13.68 million.

In related news, CEO Richard J. Daly bought 7,500 shares of the company’s stock in a transaction on Wednesday, May 17th. The shares were purchased at an average price of $4.00 per share, for a total transaction of $30,000.00. Following the completion of the transaction, the chief executive officer now directly owns 23,312 shares in the company, valued at approximately $93,248. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 15.43% of the company’s stock.

An institutional investor recently raised its position in Neuralstem stock. Blair William & Co. IL increased its stake in Neuralstem, Inc. (NASDAQ:CUR) by 171.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,343 shares of the company’s stock after buying an additional 55,115 shares during the period. Blair William & Co. IL owned approximately 0.73% of Neuralstem worth $506,000 as of its most recent SEC filing. Institutional investors own 12.46% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Neuralstem, Inc. (CUR) Reaches New 1-Year Low at $1.13” was published by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply